SGLT-2 Inhibitors Can Be Safely Started in Patients with A1C of 10%
Starting an SGLT-2 inhibitor in a patient with markedly elevated glucose (A1C 10%) is generally safe and appropriate, but requires specific risk mitigation strategies to prevent euglycemic ketoacidosis, particularly if the patient is on insulin. 1
Key Risks to Address
Euglycemic Diabetic Ketoacidosis (Most Critical Risk)
The primary concern with initiating SGLT-2 inhibitors in patients with severe hyperglycemia is euglycemic ketoacidosis, which can occur even with blood glucose levels of 150-250 mg/dL (8-14 mmol/L) 1. This risk is particularly elevated in:
- Patients requiring insulin (highest risk group)
- Those with poor oral intake or prolonged fasting
- Patients during acute illness or metabolic stress
Critical mitigation strategy: Maintain at least low-dose insulin when starting an SGLT-2 inhibitor. Do not discontinue insulin entirely, even if glucose control improves 1.
Hypoglycemia Risk
With an A1C of 10%, the patient likely has poor baseline control. However, when adding an SGLT-2 inhibitor 2:
- Reduce insulin dose by approximately 20% at initiation if patient is on insulin
- Discontinue or wean sulfonylureas to prevent hypoglycemia
- Monitor glucose closely for the first 4 weeks
The absolute risk of hypoglycemia with SGLT-2 inhibitors alone is low, but combination with insulin or sulfonylureas increases this risk 1.
Volume Depletion and Acute Kidney Injury
SGLT-2 inhibitors cause osmotic diuresis (eliminating 60-100g glucose/day), which can lead to volume depletion 3, 4:
- Assess volume status before initiation
- Reduce concurrent diuretic doses if patient is on loop or thiazide diuretics
- Educate about dehydration symptoms (lightheadedness, orthostasis, weakness)
- Follow up to reassess volume status after initiation
An initial reversible eGFR decline of 3-5 mL/min/1.73 m² is expected and does not require discontinuation 5, 4, 1.
Genitourinary Infections
Genital mycotic infections occur in 6% of SGLT-2 inhibitor users (vs 1% placebo), with higher risk in women (10-15%) and uncircumcised men 1, 6:
- Counsel on genital hygiene before starting
- Most infections are easily treated with antifungals
- Rarely, severe Fournier gangrene has been reported
Urinary tract infections show no increased risk compared to other glucose-lowering drugs 6.
Practical Implementation Algorithm
Step 1: Check contraindications
- eGFR <20 mL/min/1.73 m² (do not initiate, though can continue if already on therapy) 5, 1, 4
- Pregnancy or breastfeeding 2
- Type 1 diabetes (contraindicated) 7
Step 2: Adjust background therapy
- If on insulin: Reduce total daily dose by ~20% 2
- If on sulfonylurea: Discontinue or significantly reduce dose 2
- If on loop/thiazide diuretics with tenuous volume status: Consider dose reduction 5
Step 3: Patient education (critical)
- Ketoacidosis symptoms: nausea, vomiting, abdominal pain, weakness—seek urgent care even if glucose is not extremely elevated 2
- Sick day rules: Withhold SGLT-2 inhibitor during illness, prolonged fasting, or surgery 5, 4
- Maintain adequate hydration
- Genital hygiene practices
Step 4: Monitoring
- Close glucose monitoring for first 4 weeks 2
- Reassess volume status at follow-up 5
- Expect initial eGFR dip (not a reason to stop) 5, 4, 1
- Consider blood or urine ketone monitoring capability, especially if on insulin 1
Important Caveats
Do NOT routinely use SGLT-2 inhibitors in the inpatient setting for acute hyperglycemia management 8. The risk of euglycemic ketoacidosis is heightened during acute illness, and these agents are not recommended for hospital use.
Very low-carbohydrate/ketogenic diets pose additional risk since SGLT-2 inhibitors eliminate 60-100g glucose daily, potentially exceeding dietary carbohydrate intake 3.
Bottom Line
The elevated A1C of 10% is not a contraindication to SGLT-2 inhibitor initiation—in fact, these patients may derive substantial cardiovascular and renal benefits 2, 5, 1. The key is implementing proper risk mitigation strategies, particularly maintaining insulin therapy (if applicable), educating about ketoacidosis warning signs, and establishing sick day protocols. The benefits on mortality, cardiovascular outcomes, and kidney protection typically outweigh the manageable risks when appropriate precautions are taken 1, 3, 9.